333 filings
Page 5 of 17
8-K
0bnlw92r
23 Jun 22
USPTO Issues Patent Covering Use of XPro™ for Treatment of CNS Diseases
4:00pm
8-K
nfito72qvuczhu4fj
16 Jun 22
Other Events
4:00pm
8-K
g45 9azmj68uc3l3i
1 Jun 22
Submission of Matters to a Vote of Security Holders
4:00pm
8-K/A
nu23vxnixtq12e 4hu
24 May 22
Other Events
7:44am
8-K
tk9stycaxfrme11
23 May 22
Other Events
4:04pm
8-K
c70m8kju 37
18 May 22
INmune Bio, Inc. to Present at the H.C. Wainwright Global Hybrid Investment Conference on May 24th
4:00pm
8-K
oj0wnchi ti5
10 May 22
INmune Bio, Inc. Presents Data Demonstrating XPro™ Promotes Remyelination in Gray Matter at 3rd European Conference on Neuroinflammation
4:00pm
8-K
29zlfw91
6 May 22
INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business Update
8:00am
8-K
pif3 1j0tylu
28 Apr 22
INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5
7:01am
8-K
bn4cib3
25 Apr 22
INmune Bio, Inc. to Participate at the B. Riley Neuro & Ophthalmology Conference
4:05pm
8-K
9umjitzwz8jo9p8
13 Apr 22
INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimer’s disease
5:27pm
8-K
jjczgqq20eozvyzxlbh
11 Apr 22
INmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research (AACR) Annual Meeting 2022
4:00pm
8-K
z95x0174khu4kayl5ft
5 Apr 22
INmune Bio, Inc. Highlights INKmune™ Data Featured in NK Cells in Solid Tumors Workshop at Innate Killer Summit
5:33pm
8-K
mmotrhg2vf wsji4q
31 Mar 22
INmune Bio, Inc. Announces Company’s CSO Dr. Mark Lowdell to Co-Host the “NK Cells in Solid Tumors” Workshop at Innate Killer Summit
4:53pm
8-K
3aw2czwj ti
30 Mar 22
Other Events
8:05am
8-K
bxfjb5t1
25 Mar 22
INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD™ 2022
4:22pm
8-K
g5ge2
24 Mar 22
Departure of Directors or Certain Officers
4:01pm
8-K
81yt2t9j
24 Mar 22
Entry into a Material Definitive Agreement
4:00pm